WO2004080375A3 - Vaccin - Google Patents
Vaccin Download PDFInfo
- Publication number
- WO2004080375A3 WO2004080375A3 PCT/EP2004/002643 EP2004002643W WO2004080375A3 WO 2004080375 A3 WO2004080375 A3 WO 2004080375A3 EP 2004002643 W EP2004002643 W EP 2004002643W WO 2004080375 A3 WO2004080375 A3 WO 2004080375A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunogens
- apociii
- atherosclerosis
- present
- fragments
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108010056301 Apolipoprotein C-III Proteins 0.000 abstract 4
- 102000030169 Apolipoprotein C-III Human genes 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000007505 plaque formation Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention se rapporte à de nouvelles thérapies vaccinales et à des traitements prophylactiques de maladies artériosclérotiques. On prévoit des immunogènes contenant des fragments ou dérivés spécifiques de l'Apolipoproteine C-III (ApoCIII). Les vaccins de cette invention, renfermant les immunogènes, sont puissants en terme de prévention, ou de réduction, de la formation de plaque artériosclérotique sur des périodes prolongées, ce qui a pour effet de réduire le risque que l'artériosclérose n'entraîne des maladies coronaires ou cérébrovasculaires. Font également l'objet de cette invention des méthodes de traitement ou de prévention de l'artériosclérose par vaccination active, ou vaccination passive, au moyen d'administration à un patient d'un anticorps apte à se lier à des fragments spécifiques de ApoCIII. Des anticorps monoclonaux spécifiques et leur utilisation dans la thérapie de l'artériosclérose font également l'objet de cette invention. L'invention concerne par ailleurs l'utilisation des immunogènes de cette invention dans le domaine médical, et leurs procédés de production. Les fragments d'ApoCIII formant la base des immunogènes de cette invention ainsi que les cibles d'immunothérapie passive se trouvent au sein des zones entre les nombres 45-76 d'acides aminés et, plus particulièrement, entre 12-35 de la forme adulte de l'ApoCIII humaine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0305794.0 | 2003-03-13 | ||
| GBGB0305794.0A GB0305794D0 (en) | 2003-03-13 | 2003-03-13 | Vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004080375A2 WO2004080375A2 (fr) | 2004-09-23 |
| WO2004080375A3 true WO2004080375A3 (fr) | 2005-01-13 |
Family
ID=9954733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2004/002643 WO2004080375A2 (fr) | 2003-03-13 | 2004-03-11 | Vaccin |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0305794D0 (fr) |
| WO (1) | WO2004080375A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23736A1 (es) | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
| MA45602A (fr) | 2016-07-08 | 2019-05-15 | Staten Biotechnology B V | Anticorps anti-apoc3 et leurs méthodes d'utilisation |
| MA50958A (fr) * | 2017-04-21 | 2020-10-14 | Staten Biotechnology B V | Anticorps anti-apoc3 et leurs méthodes d'utilisation |
| AU2018361957B2 (en) | 2017-10-31 | 2023-05-25 | Staten Biotechnology B.V. | Anti-ApoC3 antibodies and methods of use thereof |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| US11690901B2 (en) | 2020-03-03 | 2023-07-04 | The United States Of America, As Represented By The Secretary Of Agriculture | Southern cattle tick vaccine product |
| WO2022136466A1 (fr) | 2020-12-23 | 2022-06-30 | Argonaute RNA Limited | Traitement d'une maladie cardiovasculaire |
| EP4402263A2 (fr) | 2021-09-14 | 2024-07-24 | Argonaute Rna Limited | Traitement d'une maladie cardiovasculaire |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0378881A1 (fr) * | 1989-01-17 | 1990-07-25 | ENIRICERCHE S.p.A. | Peptides synthétiques et leur utilisation comme support universel pour la préparation de conjugués immunogènes convenant au développement de vaccins synthétiques |
| WO2001064008A2 (fr) * | 2000-03-03 | 2001-09-07 | Smithkline Beecham Biologicals S.A. | Vaccins |
| WO2003020765A2 (fr) * | 2001-08-31 | 2003-03-13 | Glaxosmithkline Biologicals S.A. | Vaccins |
-
2003
- 2003-03-13 GB GBGB0305794.0A patent/GB0305794D0/en not_active Ceased
-
2004
- 2004-03-11 WO PCT/EP2004/002643 patent/WO2004080375A2/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0378881A1 (fr) * | 1989-01-17 | 1990-07-25 | ENIRICERCHE S.p.A. | Peptides synthétiques et leur utilisation comme support universel pour la préparation de conjugués immunogènes convenant au développement de vaccins synthétiques |
| WO2001064008A2 (fr) * | 2000-03-03 | 2001-09-07 | Smithkline Beecham Biologicals S.A. | Vaccins |
| WO2003020765A2 (fr) * | 2001-08-31 | 2003-03-13 | Glaxosmithkline Biologicals S.A. | Vaccins |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004080375A2 (fr) | 2004-09-23 |
| GB0305794D0 (en) | 2003-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003020765A3 (fr) | Vaccins | |
| WO2001064008A3 (fr) | Vaccins | |
| WO2003090686A3 (fr) | Utilisation de proteines de choc thermique pour ameliorer l'avantage therapeutique d'une modalite de traitement non vaccinal | |
| WO2002034205A3 (fr) | Utilisation des proteines du stress pour stimuler la reponse immunitaire | |
| HUP0303173A2 (hu) | Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok | |
| WO2002056905A3 (fr) | Jeu ordonne d'echantillons d'antigenes moleculaires | |
| JP2004501101A5 (fr) | ||
| BRPI0010612B8 (pt) | vacinas | |
| WO2010067286A3 (fr) | Vaccin peptidique ige ch3 | |
| JP2006506441A5 (fr) | ||
| WO2010016912A3 (fr) | Compositions immunothérapeutiques pour le traitement de la maladie d'alzheimer | |
| WO2001053457A3 (fr) | Vaccins contre certains troubles neurodegeneratifs | |
| Johnston et al. | TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines | |
| WO2004080375A3 (fr) | Vaccin | |
| WO2005120558A3 (fr) | Procede pour la fabrication de compositions comportant des proteines de choc thermique ou de l'alpha-2-macroglobuline pour le traitement du cancer et de maladie infectieuse | |
| WO2003059385A3 (fr) | Vaccin contre le vih et procede d'utilisation | |
| WO2004081045A3 (fr) | Vaccin | |
| WO2003090687A8 (fr) | Utilisation de proteines de choc thermique pour renforcer la reponse immunitaire | |
| JP2007513992A5 (fr) | ||
| AU2003263712A1 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
| Pfützner et al. | AIT: new avenues in allergen immunotherapy | |
| WO2002060435A8 (fr) | Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer | |
| EP2359850A1 (fr) | Vaccins unitemporels | |
| WO2004081046A3 (fr) | Nouvelle composition | |
| WO2004030607A3 (fr) | Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |